Search - tctmd.com

Displaying 1 - 20 of 50

Sort: Relevancy | Date

News Daily News

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Michael O'Riordan

August 06, 2025

News Daily News

FDA Approves Triple Therapy Polypill for High Blood Pressure

Michael O'Riordan

June 10, 2025

News Conference News EAS 2025

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Yael L. Maxwell

May 08, 2025

News Daily News

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Michael O'Riordan

May 07, 2025

News Daily News

New Platelet Function, Genetic Testing Consensus Seeks to Fill Gaps—Again

Yael L. Maxwell

November 27, 2024

News Daily News

Marked LDL Lowering With Obicetrapib in HeFH: BROOKLYN

Michael O'Riordan

July 29, 2024

News Daily News

Rosuvastatin, Atorvastatin: Similar Efficacy in LODESTAR, Some Differing Signals

Yael L. Maxwell

October 19, 2023

News Daily News

Clopidogrel Bests Aspirin Monotherapy After PCI Across Risk Strata

Yael L. Maxwell

October 09, 2023

News Opinion CV Team Dispatch

October 2023 News Roundup

L.A. McKeown

October 01, 2023

News Daily News

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

Michael O'Riordan

July 20, 2023

News Conference News EAS 2023

With New LDL Goalposts in FH, Combo Therapy Must Start Early

Michael O'Riordan

May 29, 2023

News Daily News

Hypertension Drug Effects Differ From Person to Person, PHYSIC Trial Shows

L.A. McKeown

April 12, 2023

News Daily News

More AF Surveillance Needed in Chemotherapy Trials, Meta-analysis Hints

L.A. McKeown

April 06, 2023

News Daily News

Ezetimibe Plus Moderate-Dose Statins May Aid Compliance in the Elderly

Yael L. Maxwell

April 03, 2023

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for February 2023

Shelley Wood

March 01, 2023

News Daily News

Ezetimibe Plus Moderate Statin a Welcome Alternative for High-Dose Monotherapy

Todd Neale

July 20, 2022

News Daily News

Clopidogrel Superior to ‘Divine’ Aspirin Monotherapy in Secondary Prevention

Michael O'Riordan

March 30, 2022

News Opinion CV Team Dispatch

March 2022 News Roundup

L.A. McKeown

March 01, 2022

News Daily News

Heterozygous FH Diagnosed Late, Remains Undertreated

Michael O'Riordan

September 13, 2021

News Conference News ESC 2021

‘Quadpill’ Beats Monotherapy at BP Lowering: QUARTET

Caitlin E. Cox

August 31, 2021

Advertisement

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

FDA Approves Triple Therapy Polypill for High Blood Pressure

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

New Platelet Function, Genetic Testing Consensus Seeks to Fill Gaps—Again

Marked LDL Lowering With Obicetrapib in HeFH: BROOKLYN

Rosuvastatin, Atorvastatin: Similar Efficacy in LODESTAR, Some Differing Signals

Clopidogrel Bests Aspirin Monotherapy After PCI Across Risk Strata

October 2023 News Roundup

New Chronic Heart Disease Guidelines Update Roles of GDMT, Imaging, and Revascularization

With New LDL Goalposts in FH, Combo Therapy Must Start Early

Hypertension Drug Effects Differ From Person to Person, PHYSIC Trial Shows

More AF Surveillance Needed in Chemotherapy Trials, Meta-analysis Hints

Ezetimibe Plus Moderate-Dose Statins May Aid Compliance in the Elderly

TCTMD’s Top 10 Most Popular Stories for February 2023

Ezetimibe Plus Moderate Statin a Welcome Alternative for High-Dose Monotherapy

Clopidogrel Superior to ‘Divine’ Aspirin Monotherapy in Secondary Prevention

March 2022 News Roundup

Heterozygous FH Diagnosed Late, Remains Undertreated

‘Quadpill’ Beats Monotherapy at BP Lowering: QUARTET

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content